biopharmaceutical

Arcutis granted 309,000 equity awards to 40 new hires. Company seeks FDA approval to expand ZORYVE cream to treat atopic dermatitis in infants as young as 3 months.

Biofrontera to report Q1 2026 results May 14, advancing Ameluz® commercialization and clinical expansion into skin cancers and acne.

Pharvaris raises $115M through 3.87M share offering at $29.68 per share to advance oral angioedema treatments; Phase 3 data expected Q3 2026.

Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion at $31.50 per share, with concurrent patent litigation resolution for rare disease drug Firdapse.

Supernus Pharmaceuticals reports strong Q1 2026 results with $207.7M revenue, up 39% YoY. CEO Jack Khattar to present at Bank of America health care conference in May.

$ANNX set to showcase ARCHER II Phase 3 results targeting $1B+ geographic atrophy market at BofA Securities conference May 2026.

Kamada Ltd. will release Q1 2026 financial results on May 13, 2026, as the plasma-derived therapeutics company continues executing its growth strategy.

Axsome Therapeutics to present at BofA Securities and RBC Capital Markets healthcare conferences in May 2026, with webcast access for remote investors.

Gyre Therapeutics completes all-stock acquisition of Cullgen for ~$300M, creating integrated biopharmaceutical company with U.S.-China operations and commercial-stage fibrosis drug.

NewAmsterdam Pharma approved inducement grants totaling 50,400 options and 15,400 RSUs to five new non-executive employees under Nasdaq compliance rules.

Rein Therapeutics prices $50M stock offering at $1.00 per share to fund LTI-03 Phase 2 trial for idiopathic pulmonary fibrosis, with cash runway extended through 2028.

Intellia Therapeutics raises $180M via stock offering at $10.75/share to advance CRISPR gene-editing therapies, with lead underwriters Jefferies, Goldman Sachs, Citigroup.

Cell culture media bags market projected to reach $2.28B by 2035 from $1.30B in 2025, growing at 5.8% CAGR amid biotech manufacturing expansion.

Oruka Therapeutics prices 9.66M shares at $72.50 in upsized offering, raising $700.4M with potential additional proceeds from underwriter overallotment option.

AAV vector manufacturing market to surge from $874M (2025) to $5.2B (2034) as gene therapy breakthroughs drive demand for specialized production infrastructure.

Quantum BioPharma engages two marketing firms for $275K to boost investor awareness and corporate branding through May 2026, signaling confidence in upcoming catalysts.

Oruka Therapeutics plans $500M public offering plus $75M underwriter option to fund monoclonal antibody pipeline for psoriasis and inflammatory conditions.

Ligand Pharmaceuticals to acquire XOMA Royalty for $39/share in $739M cash deal, expanding portfolio and raising 2026 EPS guidance.

Altimmune closed a $225M oversubscribed public offering led by Deep Track Capital. Proceeds will fund Phase 3 MASH trial initiation in H2 2026 and operational runway through data readout.

Altimmune raises $225M in oversubscribed offering to fund Phase 3 MASH trial, pricing 64.25M shares at $3.00 each.